Publications

Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood cancer journal. 2024. PMID: 39414769

Hillege LE, Trepka KR, Ziemons J, Aarnoutse R, Guthrie BGH, de Vos-Geelen J, Iersel LV, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Turnbaugh PJ, Smidt ML. Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients. medRxiv : the preprint server for health sciences. 2024. PMID: 39484258

Hillege LE, Trepka KR, Ziemons J, Aarnoutse R, Guthrie BGH, de Vos-Geelen J, Iersel LV, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Turnbaugh PJ, Smidt ML. Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients. medRxiv : the preprint server for health sciences. 2024. PMID: 39484258

Cho NW, Guldberg SM, Nabet BY, Yu JZ, Kim EJ, Hiam-Galvez KJ, Yee JL, DeBarge R, Tenvooren I, Ashitey NA, Lynce F, Dillon DA, Rosenbluth JM, Spitzer MH. T cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL-1 and TNFα Inflammation. Cancer immunology research. 2024. PMID: 39404741

Haugh AM, Daud AI. Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events. The Journal of clinical investigation. 2024. PMID: 39403930

Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). European urology. 2024. PMID: 39394013

Sidhom F, Patel S, Desai A, Basu A. High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma-Are we there yet? Clinical genitourinary cancer. 2024. PMID: 39536416

Ho C, Zhu S, Gooley T, Gujral TS, Lynch RC, Poh C, Shadman M, Smith SD, Tseng Y, Gopal AK. A phase 2 study of frontline pembrolizumab in follicular lymphoma. Volume 5 of Issue 6 EJHaem. 2024. PMID: 39691260

Ai W, Zuo Z. Synthesis, optimization and antitumor activity evaluation of sulfonyl benzoyl hydrazide derivatives as novel human LSD1 inhibitors. Bioorganic & medicinal chemistry letters. 2024. PMID: 39384076

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024. PMID: 39385035

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024. PMID: 39385035

Bhasin N, LeBlanc DM, Yates S, Eichbaum Q, Pham A, Sharma D, Zhang L, Vichinsky EP, Sarode R. Physician perspectives about the diagnosis and management of acute chest syndrome. Transfusion. 2024. PMID: 39373054

K. Zwart, M. Braat, F. van der Baan, A. May, J. Roodhart, D. Al-Toma, J. Otten, M. Los,
T. Oostergo, R. Fijneman, J. van Dodewaard-de Jong, C. Punt, G. Meijer, J. Lagendijk,
M. Koopman, M. Intven, G. M. Bol. Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with less than 10 metastases: A multicenter pilot study (NCT05375708) Clinical and Translational Radiation Oncology. 2024. PMID:

Zwart K, Braat MNGJA, van der Baan FH, May AM, Roodhart JML, Al-Toma D, Otten JMMB, Los M, Oostergo T, Fijneman RJA, van Dodewaard-de Jong JM, Punt CJA, Meijer G, Lagendijk JJW, Koopman M, Intven M, Bol GM. Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with ≤ 10 metastases: A multicenter pilot study (NCT05375708). Volume 49 Clinical and Translational Radiation Oncology. 2024. PMID: 39885896

Ng DL, Vuhahula E, Kimambo AH, Ndayisaba MC, Philipo GS, Mushi BP, Ho KE, Paciorek A, Illonga Z, Zhang L, Vohra P, Weidler J, Bates M, Mmbaga EJ, Van Loon K. Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study. The Lancet. Oncology. 2024. PMID: 39369731

Ng DL, Vuhahula E, Kimambo AH, Ndayisaba MC, Philipo GS, Mushi BP, Ho KE, Paciorek A, Illonga Z, Zhang L, Vohra P, Weidler J, Bates M, Mmbaga EJ, Van Loon K. Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study. The Lancet. Oncology. 2024. PMID: 39369731

Roy S, Malone S, Wing K, Chowdhury S, Kishan AU, Sun Y, Wallis CJD, Mohamad O, Jia AY, Swami U, Zaorsky NG, Morgan SC, Ong M, Agarwal N, Spratt DE, Small EJ, Saad F. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial. JAMA network open. 2024. PMID: 39405060

Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Haddadin M, Jain N, Jonas B, Kirby S, Liedtke M, Litzow M, Logan A, Long M, Luger S, Mangan JK, Massaro S, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Saygin C, Schwartz M, Shami P, Tomlinson B, Webster J, Awotiwon A, Stehman K. Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 39413812

Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Haddadin M, Jain N, Jonas B, Kirby S, Liedtke M, Litzow M, Logan A, Long M, Luger S, Mangan JK, Massaro S, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Saygin C, Schwartz M, Shami P, Tomlinson B, Webster J, Awotiwon A, Stehman K. Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 39413812

Othman T, Logan AC, Muffly L, Leonard J, Park J, Shah B, Aldoss I. The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 39413830